Carcinoma is treated in a patient by administration of Rhodamine-123 (Rh-123) orally or by intravenous injection of a treatment solution of Rh-123, ethyl alcohol, dextrose, and water in an amount sufficient to effect in vivo destruction of cancer cells. The treatment solution is made by mixing a stock solution of Rh-123 in a solution of 95% ethyl alcohol and 5% water (by volume) with a solution of 5% (by weight) dextrose in water. For prostate cancer, treatment is controlled by measuring the level of prostate specific antigen (PSA), or prostate specific acid phosphatase in the blood of the patient.
CROSS-REFERENCE TO RELATED APPLICATION(S)
This is a continuation-in-part of application Ser. No. 08/816,411, filed March 13, 1997, abandoned which is a continuation of application Ser. No. 08/516,004, filed Aug. 16, 1995 abandoned.
